Aligos Therapeutics, Inc. (ALGS) DCF Valuation

Aligos Therapeutics, Inc. (ALGS) DCF Valuation
  • ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
  • ✓ Design Profissional: Modelos Confiáveis ​​E Padrão Da Indústria
  • ✓ Pré-Construídos Para Uso Rápido E Eficiente
  • ✓ Não É Necessária Experiência; Fácil De Seguir

Aligos Therapeutics, Inc. (ALGS) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Whether you’re an investor or analyst, this (ALGS) DCF Calculator is your go-to resource for accurate valuation. Equipped with real data from Aligos Therapeutics, Inc., you can adjust forecasts and immediately observe the effects.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .0 .0 4.4 13.9 15.5 19.9 25.4 32.5 41.6 53.2
Revenue Growth, % 0 0 0 219.04 11.66 27.92 27.92 27.92 27.92 27.92
EBITDA -49.9 -105.1 -124.5 -93.9 -85.1 -4.0 -5.1 -6.5 -8.3 -10.6
EBITDA, % 100 100 -2857.15 -675.24 -547.74 -20 -20 -20 -20 -20
Depreciation 2.3 3.3 3.8 3.7 3.1 13.2 16.9 21.6 27.7 35.4
Depreciation, % 100 100 86.67 26.43 19.76 66.57 66.57 66.57 66.57 66.57
EBIT -52.2 -108.4 -128.3 -97.6 -88.1 -4.0 -5.1 -6.5 -8.3 -10.6
EBIT, % 100 100 -2943.82 -701.66 -567.5 -20 -20 -20 -20 -20
Total Cash 117.7 243.5 190.7 125.8 135.7 19.9 25.4 32.5 41.6 53.2
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 .0 .0 .0 .0
Account Receivables, % 100 100 0 0 0
Inventories .0 .0 .0 .0 .0 7.9 10.2 13.0 16.6 21.3
Inventories, % 100 100 0 0 0 40 40 40 40 40
Accounts Payable 3.8 3.3 3.0 4.7 2.5 12.7 16.2 20.8 26.6 34.0
Accounts Payable, % 100 100 69.17 34.06 16.21 63.89 63.89 63.89 63.89 63.89
Capital Expenditure -2.8 -2.1 -.9 -.9 .0 -1.1 -1.4 -1.8 -2.3 -2.9
Capital Expenditure, % 100 100 -20.46 -6.78 -0.12235 -5.47 -5.47 -5.47 -5.47 -5.47
Tax Rate, % -0.91501 -0.91501 -0.91501 -0.91501 -0.91501 -0.91501 -0.91501 -0.91501 -0.91501 -0.91501
EBITAT -52.3 -108.5 -128.5 -97.7 -88.9 -4.0 -5.1 -6.5 -8.3 -10.6
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -49.0 -107.7 -125.9 -93.2 -88.1 2.4 9.5 12.2 15.6 20.0
WACC, % 14.33 14.33 14.33 14.33 14.33 14.33 14.33 14.33 14.33 14.33
PV UFCF
SUM PV UFCF 37.0
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 20
Terminal Value 165
Present Terminal Value 85
Enterprise Value 122
Net Debt -125
Equity Value 246
Diluted Shares Outstanding, MM 25
Equity Value Per Share 9.90

What You Will Get

  • Real ALGS Financials: Access historical and projected data for precise valuation.
  • Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
  • Dynamic Calculations: Intrinsic value and NPV are computed automatically.
  • Scenario Analysis: Evaluate various scenarios to assess Aligos Therapeutics' future prospects.
  • User-Friendly Design: Tailored for experts while remaining easy to navigate for newcomers.

Key Features

  • Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation models tailored for Aligos Therapeutics, Inc. (ALGS).
  • WACC Calculator: Pre-configured Weighted Average Cost of Capital sheet with adjustable inputs specific to the biotech sector.
  • Customizable Forecast Assumptions: Adjust growth rates, capital expenditures, and discount rates to align with Aligos Therapeutics' strategic goals.
  • Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios pertinent to Aligos Therapeutics, Inc. (ALGS).
  • Interactive Dashboard and Charts: Visual representations summarize essential valuation metrics for streamlined analysis.

How It Works

  1. Download the Template: Get instant access to the Excel-based ALGS DCF Calculator.
  2. Input Your Assumptions: Adjust the yellow-highlighted cells for growth rates, WACC, margins, and more.
  3. Instant Calculations: The model automatically updates Aligos Therapeutics’ intrinsic value.
  4. Test Scenarios: Simulate different assumptions to evaluate potential valuation changes.
  5. Analyze and Decide: Use the results to guide your investment or financial analysis.

Why Choose Aligos Therapeutics, Inc. (ALGS)?

  • Innovative Solutions: Focused on developing transformative therapies for viral infections and liver diseases.
  • Expert Team: Comprised of industry veterans with extensive experience in drug development.
  • Robust Pipeline: Multiple clinical-stage programs targeting significant unmet medical needs.
  • Strategic Partnerships: Collaborations with leading organizations to enhance research and development.
  • Commitment to Patients: Dedicated to improving the lives of patients through groundbreaking science.

Who Should Use This Product?

  • Professional Investors: Develop comprehensive and accurate valuation models for assessing Aligos Therapeutics, Inc. (ALGS).
  • Corporate Finance Teams: Evaluate valuation scenarios to inform strategic decisions within the organization.
  • Consultants and Advisors: Deliver precise valuation insights for clients interested in Aligos Therapeutics, Inc. (ALGS).
  • Students and Educators: Utilize real-world data to enhance learning and practice in financial modeling.
  • Biotech Enthusiasts: Gain insights into how biotech companies like Aligos Therapeutics, Inc. (ALGS) are valued in the market.

What the Template Contains

  • Preloaded ALGS Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
  • DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
  • Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
  • Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
  • Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
  • Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.

No products were found matching.